Debby Bogaert - Infectious Diseases

Author Information

Debby Bogaert is affiliated with The University of Edinburgh, specifically with the MRC Centre for Inflammation Research located at The Queen's Medical Research Institute in Edinburgh, UK. Her work is deeply entrenched in the field of Infectious Diseases, with a particular focus on the microbiome and its interactions with infectious agents and the immune system.

Research Contributions

Debby Bogaert has made significant contributions to understanding the role of the microbiome in health and disease. Her recent research includes exploring the impacts of early-life antibiotics on the infant gut microbiome, the effects of viral infections on immune profiles, and the implementation of corticosteroids in treating COVID-19. Her work also delves into the dynamics of microbial markers for colorectal neoplasia risk prediction and the interactions between influenza vaccines and pneumococcal colonisation. These studies highlight her commitment to advancing knowledge in microbial and immune system interactions, particularly in the context of infectious diseases.

Aliases

Debby Bogaert is also known by various aliases including D. Bogaert and D Bogaert.

Publication and Citation Metrics

Metric	Value
Total Citation Count	13,892
h-index	53
Total Number of Papers	214

Publications:

Gut microbiota-derived metabolite Trimethylamine-N-oxide (TMAO) and multiple health outcomes: an umbrella review and updated meta-analysis.

DOI: 10.1093/ajcn/nqac074

Year: 2022

Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial

DOI: 10.1038/s41467-022-28525-z

Year: 2022

Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study

DOI: 10.1016/S2589-7500(22)00018-8

Year: 2022

A systematic review of microbial markers for risk prediction of colorectal neoplasia.

DOI: 10.1038/s41416-022-01740-7

Year: 2022

Early-life viral infections are associated with disadvantageous immune and microbiota profiles and recurrent respiratory infections.

DOI: 10.1038/s41564-021-01043-2

Year: 2022

Prior upregulation of interferon pathways in the nasopharynx impacts viral shedding following live attenuated influenza vaccine challenge in children

DOI: 10.1016/j.xcrm.2022.100516

Year: 2022

Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK

DOI: 10.1016/S2213-2600(21)00175-2

Year: 2021

Pre-Existing Upregulation of Interferon Pathways in the Nasopharynx Impacts Viral Shedding Following Live Attenuated Influenza Vaccine Challenge in Children

DOI: 10.2139/ssrn.3895934

Year: 2021

The oropharyngeal microbiome of COPD patients and controls in a livestock dense area

DOI: 10.1183/13993003.congress-2021.oa99

Year: 2021

The effect of live attenuated influenza vaccine on pneumococcal colonisation densities among children aged 24–59 months in The Gambia: a phase 4, open label, randomised, controlled trial

DOI: 10.1016/s2666-5247(21)00179-8

Year: 2021

How Do Vaccines Work?

What is an Apicoplast?

Which Infections Are Most Affected?

What Are the Applications of Proteomics in Infectious Diseases?

Are There Different Types of Condoms?

What is Airborne Transmission?

How Do MHC Genes Influence Immune Response?

Are There Risks Associated with Imaging?

What are the different types of condoms available?

What Are the General Principles of Treatment?

Partnered Content Networks

Relevant Topics